Sage and Biogen's SAGE-324 Fails in Mid-Stage Study for Essential Tremor, Stock Drops 25%

Jul 24, 2024, 12:11 PM

Sage Therapeutics and Biogen have announced the topline results from their Phase 2 KINETIC 2 study of SAGE-324 for the treatment of essential tremor. The mid-stage trial did not demonstrate statistically significant differences between any dose of SAGE-324 and placebo in the change from baseline for the primary endpoint. As a result, Biogen and Sage do not plan to conduct further studies for this neurological disorder drug. This failure marks another setback for Biogen's $3 billion alliance with Sage Therapeutics. The experimental pill failed to quell involuntary muscle shaking in patients with essential tremor. Following the announcement, Sage Therapeutics' stock dropped by 25%.